NCT03771963View on ClinicalTrials.gov

Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) at the End of Shelf Life in Healthy Adults

PHASE3CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

March 28, 2019

Primary Completion Date

October 14, 2019

Study Completion Date

March 13, 2020

Conditions
Dengue Fever
Interventions
BIOLOGICAL

Tetravalent Dengue Vaccine (TDV)

TDV SC injection.

Trial Locations (2)

67502

Hutchinson Clinic, Hutchinson

92805

Anaheim Clinical Trials, LLC, Anaheim

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY